This proposal represents a response to Program Announcement PA-03-127, a Program intended to support """"""""Integrative and Collaborative Approaches to Research"""""""". The current application is specifically designed to """"""""integrate"""""""" Metabolomics and Pharmacogenomics to achieve a deeper understanding of the drug-response phenotype and to accelerate the establishment of genotype-phenotype correlations for drug response. Metabolomics is the study of metabolism at the """"""""global"""""""" level and involves studies of the """"""""metabolome"""""""", the entire repertoire of small molecules present in cells and/or tissues. The identities, concentrations and fluxes of these compounds represent the final product of interactions among gene sequence, gene expression, protein expression andthe cellular environment, an """"""""environment"""""""" that - in the clinical setting - includes drug exposure. Metabolomics has been identified as an important area for development under the NIH Roadmap Initiative. Pharmacogenomics is the study of the role of inheritance in individual variation in the drug response phenotype - with serious adverse drug reactions at one end of that phenotypic spectrum and lack of the desired therapeutic effect at the other. We believe that the inclusion of Metabolomic data as an additional, and highly informative """"""""intermediate phenotype"""""""" might significantly enhance our ability to understand and predict individual variation in response to therapeutic agents. We propose to test that hypothesis by adding Metabolomic analyses to ongoing Pharmacogenomic studies already funded by the NIH. Collaborating Metabolomics-Pharmacogenomics research teams will test the hypothesis that the application of Metabolomics might identify """"""""signatures"""""""" uniquely related to the drug response phenotype, using representatives of two important drug classes, an HMG CoA reductase inhibitor (simvastatin) and a specific serotonin reuptake inhibitor (escitalopram). The proposed effort to join Metabolomics and Pharmacogenomics represents an ideal example of """"""""Integrative and Collaborative Approaches to Research"""""""".

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Resource-Related Research Projects (R24)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BST-R (50))
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Schools of Medicine
United States
Zip Code
Liu, Duan; Ray, Balmiki; Neavin, Drew R et al. (2018) Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. Transl Psychiatry 8:10
Athreya, Arjun; Iyer, Ravishankar; Neavin, Drew et al. (2018) Augmentation of Physician Assessments with Multi-Omics Enhances Predictability of Drug Response: A Case Study of Major Depressive Disorder. IEEE Comput Intell Mag 13:20-31
Elbadawi-Sidhu, Mona; Baillie, Rebecca A; Zhu, Hongjie et al. (2017) Pharmacometabolomic signature links simvastatin therapy and insulin resistance. Metabolomics 13:
Neavin, Drew; Kaddurah-Daouk, Rima; Weinshilboum, Richard (2016) Pharmacometabolomics informs Pharmacogenomics. Metabolomics 12:
Gupta, M; Neavin, D; Liu, D et al. (2016) TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Mol Psychiatry 21:1717-1725
Rotroff, Daniel M; Oki, Noffisat O; Liang, Xiaomin et al. (2016) Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. Front Pharmacol 7:135
Kaddurah-Daouk, R; Weinshilboum, R; Pharmacometabolomics Research Network (2015) Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine. Clin Pharmacol Ther 98:71-5
Rotroff, D M; Shahin, M H; Gurley, S B et al. (2015) Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. CPT Pharmacometrics Syst Pharmacol 4:669-79
Krauss, R M; Zhu, H; Kaddurah-Daouk, R (2013) Pharmacometabolomics of statin response. Clin Pharmacol Ther 94:562-5
Perroud, Bertrand; Jafar-Nejad, Paymaan; Wikoff, William R et al. (2013) Pharmacometabolomic signature of ataxia SCA1 mouse model and lithium effects. PLoS One 8:e70610

Showing the most recent 10 out of 37 publications